Pharmaceutical

Avalyn raises $175m in funding to develop inhaled IPF drugs

The funding was part of an oversubscribed Series C financing that will be used to advance its lead IPF therapies into Phase II trials.

Sep 27, 2023 - 20:00
Avalyn raises $175m in funding to develop inhaled IPF drugs
The funding was part of an oversubscribed Series C financing that will be used to advance its lead IPF therapies into Phase II trials.
Read the original article

Tags:

Previous Article

Glenmark to market Winlevi in Europe and South Africa after Cosmo deal

Next Article

Galecto downsizes by 70% following Phase II trial failure

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Drug shortages challenge type 2 diabetes patients in the UK

Drug shortages challenge type 2 diabetes patients in th...

Jan 27, 2024

Study finds same small rise in breast cancer risk in many forms of hormonal birth control

Study finds same small rise in breast cancer risk in ma...

Mar 22, 2023

Over half of world’s population not covered by essential healthcare services

Over half of world’s population not covered by essentia...

Sep 23, 2023